Pre-clinical characterization of aryloxypyridine amides as histamine H 3 receptor antagonists: Identification of candidates for clinical development

Bioorganic and Medicinal Chemistry Letters

Volumn 20, Issue 14, 2010, Pages 4210-4214

  Letavic, Michael A ^a   Aluisio, Leah ^a   Atack, John R ^a   Bonaventure, Pascal ^a   Carruthers, Nicholas I ^a   Dugovic, Christine ^a   Everson, Anita ^a   Feinstein, Mark A ^a   Fraser, Ian C ^a   Hoey, Kenway ^a   Jiang, Xiaohui ^a   Keith, John M ^a   Koudriakova, Tatiana ^a   Leung, Perry ^a   Lord, Brian ^a   Lovenberg, Timothy W ^a   Ly, Kiev S ^a   Morton, Kirsten L ^a   Timothy Motley, S ^a   Nepomuceno, Diane ^a   Rizzolio, Michele ^a   Rynberg, Raymond ^a   Sepassi, Kia ^a   Shelton, Jonathan ^a   more..

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Histamine; Histamine H3

Indexed keywords

AMIDE; HISTAMINE H3 RECEPTOR; HISTAMINE H3 RECEPTOR ANTAGONIST; LIGAND;

ANIMAL CELL; ARTICLE; BRAIN; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DRUG PENETRATION; DRUG RECEPTOR BINDING; DRUG SOLUBILITY; HUMAN; HUMAN CELL; IN VITRO STUDY; MEDICAL LITERATURE; MOUSE; NONHUMAN; RAT;

AMIDES; ANIMALS; AZEPINES; DRUG EVALUATION, PRECLINICAL; HISTAMINE H3 ANTAGONISTS; PYRIDINES; RATS;

RATTUS;

EID: 77953871163     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2010.05.041     Document Type: Article

References (14)

1. Gemkow M.J., Davenport A.J., Harich S., Ellenbroek B.A., Cesura A., and Hallett D. Drug Discovery Today 14 (2009) 509
2. Esbenshade T.A., Browman K.E., Bitner R.S., Strakhova M., Cowart M.D., and Brioni J.D. Br. J. Pharmacol. 154 6 (2008) 1166
3. Sander K., Kottke T., and Stark H. Biol. Pharm. Bull. 31 12 (2008) 2163
4. Stocking E.M., and Letavic M.A. Curr. Top. Med. Chem. 8 11 (2008) 988
5. Letavic M.A., Barbier A.J., Dvorak C.A., and Carruthers N.I. Prog. Med. Chem. 44 (2006) 181
6. Celanire S., Wijtmans M., Talaga P., Leurs R., and de Esch I.J.P. Drug Discovery Today 10 (2005) 1613
7. Apodaca R., Dvorak C.A., Xiao W., Barbier A.J., Boggs J.D., Wilson S.J., Lovenberg T.W., and Carruthers N.I. J. Med. Chem. 46 (2003) 3938
8. Letavic M.A., Keith J.M., Ly K.S., Bonaventure P., Feinstein M.A., Lord B., Miller K.L., Motley S.T., Nepomuceno D., Sutton S.W., and Carruthers N.I. Bioorg. Med. Chem. Lett. 18 (2008) 5796
9. Dvorak C.A., Apodaca R., Xiao W., Jablonowski J.A., Bonaventure P., Dugovic C., Shelton J., Lord B., Miller K., Dvorak L.K., Lovenberg T.W., and Carruthers N.I. Eur. J. Med. Chem. 44 (2009) 4098
10. Ly K.S., Letavic M.A., Keith J.M., Miller J.M., Stocking E.M., Barbier A.J., Bonaventure P., Lord B., Jiang X., Boggs J.D., Dvorak L., Miller K.L., Nepomuceno D., Wilson S.J., and Carruthers N.I. Bioorg. Med. Chem. Lett. 18 (2008) 39
11. Keith, J. M.; Letavic, M. A.; Ly, K. S.: Mani, N.; Mills, J.; Villani, F.; Zhong, H. M. U.S. 20070281923.
12. Letavic M.A., and Ly K.S. Tetrahedron Lett. 48 (2007) 2339
13. 3 activity) we are unable to distinguish between antagonists versus inverse agonists
14. +/daughter was 112.09 95.1 m/z). The concentration for each sample was calculated from the peak area of the chromatographic signal and the slope from the corresponding standard curve.